{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-032324","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.537761+00:00","generated_at":"2026-06-13T10:29:46.742919+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"EyePoint appoints Jay Duker as CEO; Nancy Lurker becomes Executive Vice Chair","bullets":["Effective July 10, 2023, Jay Duker, M.D., promoted from COO/President to President and CEO and appointed to the Board.","Nancy Lurker transitions to Executive Vice Chair; annual base salary set at $455,000 with target bonus of 45%.","Duker receives base salary of $650,000, target bonus of 60%, and initial equity grants: 100,000 options + 50,000 RSUs.","Lurker receives options for 66,666 shares and 33,334 RSUs; she continues as Board member and Vice Chair.","Transition part of long-term succession plan; Company highlights strong balance sheet and upcoming Phase 2 trial readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-032324","json":"https://secwatch.observer/filing/0000950170-23-032324.json","markdown":"https://secwatch.observer/filing/0000950170-23-032324.md","text":"https://secwatch.observer/filing/0000950170-23-032324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/eypt-20230710.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:29:46.742919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1739b2a4f4","claim":"Jay S. Duker was appointed as President and Chief Executive Officer at EyePoint, Inc..","evidence_excerpt":"the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"aa0819083e","claim":"Jay S. Duker was appointed as Director at EyePoint, Inc..","evidence_excerpt":"appointed Dr. Duker to fill the vacancy for the newly created directorship","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cb101e9ce8","claim":"Nancy S. Lurker changed role as Executive Vice Chair at EyePoint, Inc..","evidence_excerpt":"Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017023032324/0000950170-23-032324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"Executive Vice Chair"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}